Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. Lercadip
2. Lercanidipine Hydrochloride
3. Lerdip
4. Methyl-1,1-dimethyl-2-(n-(3,3-diphenylpropyl)-n-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
5. Rec 15-2375
6. Rec-15-2375
7. Zanidip
1. 100427-26-7
2. Lercanidipine [inn]
3. Lercanil
4. Lercanidipine (inn)
5. V7xtj4r0bh
6. Masnidipine
7. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl Ester
8. 5-o-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-o-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
9. 1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl Methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
10. 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
11. 3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
12. Lercanil (tn)
13. Ncgc00167492-01
14. Unii-v7xtj4r0bh
15. Lercanidipine [inn:ban]
16. Lercanadipine
17. 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic Acid O5-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] Ester O3-methyl Ester
18. Lercanidipine [mi]
19. Schembl25268
20. Lercanidipine [who-dd]
21. Chembl250270
22. Schembl6846222
23. Dtxsid2048327
24. Chebi:135930
25. Hms3604g05
26. Bcp21318
27. Hy-b0612
28. Bbl029074
29. S5861
30. Stk639861
31. Akos005571238
32. Db00528
33. Sdccgsbi-0633690.p001
34. Ncgc00167492-02
35. Ncgc00167492-11
36. (+-)-2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl Methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
37. Ac-15409
38. As-75252
39. Ft-0631006
40. C13971
41. D08111
42. 427l267
43. A800200
44. A929939
45. Q410492
46. Sr-01000884000
47. Sr-01000884000-1
48. [2-oxo-3-(3-trifluoromethyl-phenoxy)-propyl]-phosphonic
49. 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl Methyl (4rs)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
50. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl Methyl Ester
51. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl Methyl Ester
52. O5-[1-[3,3-diphenylpropyl(methyl)amino]-2-methyl-propan-2-yl] O3-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
| Molecular Weight | 611.7 g/mol |
|---|---|
| Molecular Formula | C36H41N3O6 |
| XLogP3 | 6.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 13 |
| Exact Mass | 611.29953604 g/mol |
| Monoisotopic Mass | 611.29953604 g/mol |
| Topological Polar Surface Area | 114 Ų |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 1090 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
Lercanidipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Lercanidipine is similar to other peripheral vasodilators. Lercanidipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
C08CA13
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
C - Cardiovascular system
C08 - Calcium channel blockers
C08C - Selective calcium channel blockers with mainly vascular effects
C08CA - Dihydropyridine derivatives
C08CA13 - Lercanidipine
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
About the Company : Cohance Lifesciences is a leading CDMO and API platform delivering products and services across the full molecule lifecycle, from development to commercialization. With strong expe...
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
About the Company : Cohance Lifesciences is a leading CDMO and API platform delivering products and services across the full molecule lifecycle, from development to commercialization. With strong expe...
About the Company : Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and r...
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
About the Company : Octavius Pharma is a global leader in Directly Compressible Granules with over 45 years of experience in formulation development, manufacturing, and commercialization. Its portfoli...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
About the Company : Honour is a leading global CDMO and trusted manufacturer of specialty chemicals and ingredients, with seven world-class facilities meeting global safety and quality standards. Thro...
About the Company : Shamrock Pharmachemi Pvt Ltd. is a globally recognized API leader with 26+ years in human and veterinary pharmaceuticals. Operating in 40+ countries, it owns two Gujarat facilities...
Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.
About the Company : Cosma S.p.A., part of the CFM Group with AMSA and Clarochem Ireland, is the group’s largest manufacturing site in Bergamo, Italy. With 130,000L glass-lined reaction volume and ov...
About the Company : CTX is one of the youngest and fastest-growing Indian API and Intermediate manufacturing companies doing business in over 70 countries. In these five years, all my thoughts and act...

About the Company : Shouyuan chemical (one of the leading chemicals supplier in China) specializes in manufacturing, supplying, and custom synsthesis latest chemicals. Our products cover all kinds of ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 99-61-6
End Use API : Lercanidipine
About The Company : Indian Drugs And Chemicals supplies quality products using modern technologies, supported by strong industry expertise. The company serves global markets with a...
CAS Number : 14205-39-1
End Use API : Lercanidipine
About The Company : Litmus Organics Pvt. Ltd., established in 2005, aims to be a leading chemical manufacturer in India. Equipped with the latest technology and testing facilities,...

META NITRO BENZALDEHYDE (3 - NITRO BENZALDEHYDE)
CAS Number : 99-61-6
End Use API : Lercanidipine
About The Company : Rupal Chemicals gradually entered into the field of manufacturing Organic Peroxides, the proccesses were developed in its own sophisticated R&D laboratory and i...

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyr...
CAS Number : CAS-74936-72-4
End Use API : Lercanidipine
About The Company : Venkata Narayana Active Ingredients (Formerly Nutra Specialties Private Limited) Promoted by a well-known business house of India, Mr. Abhaya Kumar Jain who has...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
63
PharmaCompass offers a list of Lercanidipine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lercanidipine manufacturer or Lercanidipine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lercanidipine manufacturer or Lercanidipine supplier.
A Lercadip manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lercadip, including repackagers and relabelers. The FDA regulates Lercadip manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lercadip API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lercadip manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Lercadip supplier is an individual or a company that provides Lercadip active pharmaceutical ingredient (API) or Lercadip finished formulations upon request. The Lercadip suppliers may include Lercadip API manufacturers, exporters, distributors and traders.
click here to find a list of Lercadip suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Lercadip DMF (Drug Master File) is a document detailing the whole manufacturing process of Lercadip active pharmaceutical ingredient (API) in detail. Different forms of Lercadip DMFs exist exist since differing nations have different regulations, such as Lercadip USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lercadip DMF submitted to regulatory agencies in the US is known as a USDMF. Lercadip USDMF includes data on Lercadip's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lercadip USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lercadip suppliers with USDMF on PharmaCompass.
A Lercadip written confirmation (Lercadip WC) is an official document issued by a regulatory agency to a Lercadip manufacturer, verifying that the manufacturing facility of a Lercadip active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lercadip APIs or Lercadip finished pharmaceutical products to another nation, regulatory agencies frequently require a Lercadip WC (written confirmation) as part of the regulatory process.
click here to find a list of Lercadip suppliers with Written Confirmation (WC) on PharmaCompass.
Lercadip Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lercadip GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lercadip GMP manufacturer or Lercadip GMP API supplier for your needs.
A Lercadip CoA (Certificate of Analysis) is a formal document that attests to Lercadip's compliance with Lercadip specifications and serves as a tool for batch-level quality control.
Lercadip CoA mostly includes findings from lab analyses of a specific batch. For each Lercadip CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lercadip may be tested according to a variety of international standards, such as European Pharmacopoeia (Lercadip EP), Lercadip JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lercadip USP).